Science Current Events | Science News | Brightsurf.com
 

ESMO publishes updated guidelines on cancer care

July 09, 2010
Enhanced and revised documents provide vital, evidence-based information for treating cancer

The European Society for Medical Oncology (ESMO) just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients.

The ESMO Clinical Practice Guidelines (CPG) offer vital, evidence-based information including the incidence of the malignancy, diagnostic criteria, staging of disease and risk assessment, treatment plans and follow-up.

Formerly known as the ESMO Clinical Recommendations, the ESMO Clinical Practice Guidelines are intended to provide users with a set of requirements for the highest standard of care for cancer patients.

"The Clinical Practice Guidelines are central to ESMO's mission, which is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice," said ESMO President Prof David Kerr.

A growing number of the new guidelines have been developed using large, multidisciplinary writing groups, ensuring optimal input from the oncology profession and a better geographic representation.

"ESMO is constantly striving to improve the care of cancer patients worldwide," said Prof Kerr. "By developing these new guidelines with the assistance of a wide range of clinicians we can help share the joint expertise of the world's best doctors from many disciplines."

The ESMO Clinical Practice Guidelines include guidelines for breast cancer, colorectal cancer and non-small-cell lung cancer that have been expanded to include more treatment details and further discussion of the importance of multidisciplinary plans for particular patient settings.

Lung cancer is now dealt with in two distinct guidelines, one covering early and locally-advanced cancer, while the other focuses on metastatic disease.

One new guideline is focused specifically on cardiotoxicity, a potential side-effect of some chemotherapeutic agents.

Four further guidelines have been rewritten, drawing on the knowledge of the global oncology community. These include guidelines on soft tissue sarcoma and bone sarcoma, and a guideline on the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.

The guideline on the prevention of chemotherapy- and radiotherapy-induced nausea was developed as the result of the 3rd Perugia Consensus Conference organized by the Multinational Association of Supportive Care in Cancer (MASCC) and ESMO.

"ESMO is striving to further increase the value of its guidelines by introducing a more multidisciplinary approach in their development, not only through the use of physical meetings but also through the ESMO Professional Networking Community," said Prof Kerr.

Other guidelines have also been reviewed:

* Pancreatic cancer: including more detail relating to treatment planning in all stages of the disease.

* epatacellular cancer: including an expanded section in surgical and medical treatment, especially targeted therapy.

* Multiple myeloma: revised according to new drug indications.

* Gastrointestinal stromal tumors (GIST): revised with more treatment-orientated details.

* Cancer, fertility and pregnancy: including more information on treatment, especially surgery and highlighting problems of breast, cervical and myeloma cancer in pregnancy as well as further details about delivery of chemotherapy, hormonal and targeted therapy, radiotherapy and supportive agents in pregnant women with cancer.

* Endometrial cancer: including a new section of histology and further guidance on treatment options in these settings.

* Management of febrile neutropenia: including more detail on treatment assessments and how to manage patients.

The new guidelines published in June represent the first stage of a process that will include guidelines for more than 55 different clinical situations, covering almost all tumor types as well as various other topics, including the therapeutic use of growth factors.

European Society for Medical Oncology


Related Clinical Practice Current Events and Clinical Practice News Articles


Neurology researchers evaluate evidence base for tests for clinical cognitive assessment
Recommendations for improving clinical cognitive testing were reported by the American Academy of Neurology's (AAN) Behavioral Neurology Section (BNS) Group, led by Kirk R. Daffner, MD, of Boston, Mass.

Simple procedure using a nasal balloon can help treat hearing loss in children
For children with a common middle-ear problem, a simple procedure with a nasal balloon can reduce the impact of hearing loss and avoid unnecessary and ineffective use of antibiotics, according to a randomized controlled trial published in CMAJ (Canadian Medical Association Journal).

Weight loss for a healthy liver
Weight loss through both lifestyle modification and bariatric surgery can significantly reduce features of nonalcoholic steatohepatitis (NASH), a disease characterized by fat in the liver, according to two new studies published in Gastroenterology, the official journal of the American Gastroenterological Association.

Future medicinal chemistry shines the spotlight on schistosomiasis
In a special free issue of Future Medicinal Chemistry, leading experts explore current and potential new treatment options for the deadly neglected tropical disease schistosomiasis.

Omega-3 fatty acids may help improve treatment and quality of life in cancer patients
Adding omega-3 fatty acids to anti-tumor medications may improve treatment response and quality of life for cancer patients according to a new study by researchers at the University Hospitals of Leicester in the United Kingdom.

New treatment may help neonatal liver disease associated with parenteral nutrition
A new study finds that exogenous glucagon-like peptide 2 (GLP-2) treatment may help fight neonatal parenteral nutrition-associated liver disease (PNALD).

New smart drug targets and reduces site-specific inflammation
Ben-Gurion University of the Negev (BGU) and University of Colorado researchers have developed a dynamic "smart" drug that targets inflammation in a site-specific manner and could enhance the body's natural ability to fight infection and reduce side effects.

New treatment for severe depression with far fewer side effects
Electroconvulsive therapy remains one of the most effective treatments for severe depression, but new UNSW research shows ultra-brief pulse stimulation is almost as effective as standard ECT, with far fewer cognitive side effects.

MD Anderson study finds one-third of colorectal cancers diagnosed before 35 are hereditary
Hereditary colorectal cancers, caused by inherited gene mutations, are relatively rare for most patients. However, researchers at The University of Texas MD Anderson Cancer Center have discovered a particularly high prevalence of hereditary cancers among those diagnosed with the disease before the age of 35.

Researchers discover a possible reason for drug resistance in breast tumors
HER2 membrane proteins play a special role in certain types of breast cancer: amplified levels of HER2 drive unrestricted cell growth.
More Clinical Practice Current Events and Clinical Practice News Articles

© 2015 BrightSurf.com